SCHEMBL1165239

SCHEMBL1165239

COc1ccc(Nc2ccnc(Cl)c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.57
RAB9A P51151 6/20 0.57
NPC1 O15118 5/20 0.57
GAA P10253 3/20 0.57
MAPK1 P28482 2/20 0.57
KDM4E B2RXH2 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
THRB P10828 1/20 0.57
RECQL P46063 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
ALDH1A1 P00352 2/20 0.50
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50
SCN9A Q15858 1/20 0.50
PIK3CA P42336 1/20 0.49
PIK3CB P42338 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24150569 0.84 EGFR (0.57) MAPTRAB9ANPC1MAPK1MEN1
SCHEMBL4000502 0.81 MAPT (0.56) MAPTRAB9ANPC1GAAMAPK1
SCHEMBL30072908 0.80 GAA (0.57) MAPTGAAMEN1KMT2ASMN1; SMN2
SCHEMBL2173982 0.80 RAB9A (0.57) MAPTRAB9ANPC1GAAMAPK1
SCHEMBL3997045 0.78 GRM4 (0.50) MAPTALDH1A1PIK3CAFGFR2HTT
SCHEMBL3996779 0.78 FGFR2 (0.47) MAPTGAAPIK3CAFGFR2
SCHEMBL17963995 0.77 TNF (0.51) MAPTSMN1; SMN2TP53GRM1
SCHEMBL23365159 0.77 CYP3A4 (0.52) MAPTRAB9ANPC1KDM4EL3MBTL1
SCHEMBL29914369 0.77 CYP3A4 (0.52) MAPTRAB9ANPC1KDM4EL3MBTL1
SCHEMBL1415496 0.77 ALDH1A1 (0.52) MAPTRAB9ANPC1GAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9512066-B2 Enhancers of protein degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2016-12-06 US disclosed
US-20120282629-A1 Enhancers of Protein Degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2012-11-08 US disclosed
EP-2488485-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-08-22 EP disclosed
WO-2011020883-A9 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-07-12 WO disclosed
WO-2011020883-A9 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-07-12 WO disclosed
WO-2011020883-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2011-02-24 WO disclosed
WO-2011020883-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2011-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120282629-A1 Enhancers of Protein Degradation HTT, HYPK, TFEB MAPT 149/4885RAB9A 2389/4885NPC1 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.